In the AD field, some clinical trials now select patients based on having aPiB-positive PET scan (Ikonomovic et al., 2008) –as evidence of incipient AD pathology – and the APOE4 risk genotype, as carriers aremore likely to develop AD. Here, APOE is linked to Alzheimer disease.